盟科药业(688373.SH)：MRX-5在澳大利亚Ⅰ期临床试验已完成并达到预期目标

智通财经10-24

智通财经APP讯，盟科药业(688373.SH)发布公告，公司自主研发的新型苯并硼唑类抗菌药MRX-5在澳大利亚的Ⅰ期临床试验已于近日完成并达到预期目标。MRX-5是一种新型苯并硼唑类抗生素，拟用于治疗分枝杆菌属，特别是由非结核分枝杆菌(non-tuberculous Mycobacteria，NTM)引起的感染。MRX-5属于新型抗耐药NTM感染新药，对常见的NTM致病菌具有良好的抗菌活性，且在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2477571627?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-24 15:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477571627","market":"us","top_or_hot":-1,"title":"盟科药业(688373.SH)：MRX-5在澳大利亚Ⅰ期临床试验已完成并达到预期目标","media":"智通财经","content":"<div>\n<p>智通财经APP讯，盟科药业(688373.SH)发布公告，公司自主研发的新型苯并硼唑类抗菌药MRX-5在澳大利亚的Ⅰ期临床试验已于近日完成并达到预期目标。MRX-5是一种新型苯并硼唑类抗生素，拟用于治疗分枝杆菌属，特别是由非结核分枝杆菌(non-tuberculous Mycobacteria，NTM)引起的感染。MRX-5属于新型抗耐药NTM感染新药，对常见的NTM致病菌具有良好的抗菌活性，且在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1198676.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>盟科药业(688373.SH)：MRX-5在澳大利亚Ⅰ期临床试验已完成并达到预期目标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n盟科药业(688373.SH)：MRX-5在澳大利亚Ⅰ期临床试验已完成并达到预期目标\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-24 15:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1198676.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，盟科药业(688373.SH)发布公告，公司自主研发的新型苯并硼唑类抗菌药MRX-5在澳大利亚的Ⅰ期临床试验已于近日完成并达到预期目标。MRX-5是一种新型苯并硼唑类抗生素，拟用于治疗分枝杆菌属，特别是由非结核分枝杆菌(non-tuberculous Mycobacteria，NTM)引起的感染。MRX-5属于新型抗耐药NTM感染新药，对常见的NTM致病菌具有良好的抗菌活性，且在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1198676.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1198676.html","article_id":"2477571627","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477571627","pubTimestamp":1729755979,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，盟科药业 发布公告，公司自主研发的新型苯并硼唑类抗菌药MRX-5在澳大利亚的Ⅰ期临床试验已于近日完成并达到预期目标。MRX-5属于新型抗耐药NTM感染新药，对常见的NTM致病菌具有良好的抗菌活性，且在动物试验和此次人体实验中显示出良好的安全性和药代动力学特性。本次临床研究结果表明，MRX-5在健康成人群体中显现出良好的安全性和耐受性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688373":"盟科药业","BK1583":"高瓴概念","MRX":"Marex Group plc","BK0239":"医药制造","BK4127":"投资银行业与经纪业","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","03347":"泰格医药"},"translate_title":"Mengke Pharmaceutical (688373. SH): The phase I clinical trial of MRX-5 in Australia has been completed and achieved the expected goal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688373":1,"03347":1,"MRX":1},"content_text":"智通财经APP讯，盟科药业(688373.SH)发布公告，公司自主研发的新型苯并硼唑类抗菌药MRX-5在澳大利亚的Ⅰ期临床试验已于近日完成并达到预期目标。MRX-5是一种新型苯并硼唑类抗生素，拟用于治疗分枝杆菌属，特别是由非结核分枝杆菌(non-tuberculous Mycobacteria，NTM)引起的感染。MRX-5属于新型抗耐药NTM感染新药，对常见的NTM致病菌具有良好的抗菌活性，且在动物试验和此次人体实验中显示出良好的安全性和药代动力学特性。此外，该药物具有相互作用少、不易耐药、可口服的特点，使其适用于长期服用以治疗慢性感染。本次临床研究结果表明，MRX-5在健康成人群体中显现出良好的安全性和耐受性。本次临床试验的成功不仅为后续临床开发提供了有力的数据支持，也为MRX-5未来在治疗NTM感染的应用前景增添了信心。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477571627"}